Beijing Bohui Innovation Soars 20% After Hib Vaccine Trial Approval
Beijing Bohui Innovation’s stock surges 20% after NMPA approves its Hib vaccine trial, opening a new revenue path and boosting investor confidence.
3 minutes to read
BOHUI INNOVATION